188 related articles for article (PubMed ID: 31862860)
21. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients.
Mercadante S; Adile C; Torta R; Varetto A; Fulfaro F; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jan; 29(1):93-7. PubMed ID: 23198976
[TBL] [Abstract][Full Text] [Related]
22. Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies.
Mercadante S; Valle A; Porzio G; Aielli F; Adile C; Ficorella C; Raineri M; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):667-71. PubMed ID: 23551065
[TBL] [Abstract][Full Text] [Related]
23. Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit.
Mercadante S; Prestia G; Ranieri M; Giarratano A; Casuccio A
Support Care Cancer; 2013 Jul; 21(7):1853-9. PubMed ID: 23400316
[TBL] [Abstract][Full Text] [Related]
24. Fentanyl for the treatment of tumor-related breakthrough pain.
Bornemann-Cimenti H; Wejbora M; Szilagyi IS; Sandner-Kiesling A
Dtsch Arztebl Int; 2013 Apr; 110(16):271-7. PubMed ID: 23671467
[TBL] [Abstract][Full Text] [Related]
25. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
26. Breakthrough cancer pain in 2020.
Løhre ET; Thronæs M; Klepstad P
Curr Opin Support Palliat Care; 2020 Jun; 14(2):94-99. PubMed ID: 32332210
[TBL] [Abstract][Full Text] [Related]
27. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Zucco F; Bonezzi C; Fornasari D
Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
[TBL] [Abstract][Full Text] [Related]
28. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
[TBL] [Abstract][Full Text] [Related]
29. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.
Katz NP; Gajria KL; Shillington AC; Stephenson JJ; Harshaw Q
Postgrad Med; 2017 Jan; 129(1):32-39. PubMed ID: 27846789
[TBL] [Abstract][Full Text] [Related]
30. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Jandhyala R; Fullarton JR; Bennett MI
J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
[TBL] [Abstract][Full Text] [Related]
32. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
Radbruch L; Torres LM; Ellershaw JE; Gatti A; Luis Lerzo G; Revnic J; Taylor D
Support Care Cancer; 2012 Mar; 20(3):565-73. PubMed ID: 21424794
[TBL] [Abstract][Full Text] [Related]
33. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
[TBL] [Abstract][Full Text] [Related]
36. The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.
Mercadante S; Adile C; Cuomo A; Aielli F; Marinangeli F; Casuccio A
Support Care Cancer; 2017 Feb; 25(2):645-649. PubMed ID: 27744534
[TBL] [Abstract][Full Text] [Related]
37. Breakthrough cancer pain: The importance of the right treatment at the right time.
O'Hagan P; Mercadante S
Eur J Pain; 2018 Aug; 22(7):1362-1374. PubMed ID: 29635732
[TBL] [Abstract][Full Text] [Related]
38. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
Mercadante S; Ferrera P; Arcuri E
Support Care Cancer; 2011 Mar; 19(3):435-8. PubMed ID: 20882391
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
40. Breakthrough Cancer Pain: Ten Commandments.
Mercadante S; Cuomo A
Value Health; 2016; 19(5):531-6. PubMed ID: 27565269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
